Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules.
When the test deems a nodule suspicious, the patient's risk of malignancy is consistent and higher than that reported in the classifier's original clinical validation study, the firm said.
In the new meta-analysis, researchers evaluated 13 independent studies and found that the Afirma GSC's ability to identify benign nodules with high sensitivity and high negative predictive value for thyroid cancer was similar to the original clinical validation study results (97% vs. 91% and 99% vs. 96%, respectively).
Additionally, the meta-analysis data showed that the Afirma test's performance surpasses that shown in the original study when predicting the risk of malignancy in nodules labeled suspicious (65% positive predictive value vs. 47%).
The findings were presented at the ENDO 2022 Annual Conference held from June 11 through June 14 in Atlanta.